Cath Lab Digest - February 2008 - (Page 1)

Ask the Clinical Instructor: Todd Ginapp, EMT-P, RCIS, FSICP Calculating cardiac output Page 50 Clinical Editor’s Corner: Morton Kern, MD Avoiding Medication Mistakes Page 4 Februar y 2008, vol.16, no.2 A Product, News and Clinical Update for the Cardiac Catheterization Laboratory Specialist Cath Lab Spotlight Clinical Trial Update ENDEAVOR IV: A zotarolimus-eluting stent versus a paclitaxel-eluting stent in a randomized clinical trial Cath Lab Digest talks with Martin B. Leon, MD Cath lab staff. Back, left to right: Bob Beyerlein RCIS, Michael Sullivan RCIS, John Traxler RT, Kelly Tacey CCA, and Debbie Carter LPN. Front, left to right: Melissa Birch RN, Chandra Rasmussen RN and Christine Wascher CCA. Professor of Medicine, Columbia University Medical Center, Founder and Chairman Emeritus of the Cardiovascular Research Foundation, New York, New York and Principal Investigator of the ENDEAVOR III and ENDEAVOR IV trials. The Endeavor Stent is currently under review for approval by the FDA. Medtronic presented pre-clinical and clinical data to an FDA Advisory Panel on October 10, 2007. What is unique about the Endeavor stent? All drug-eluting stents are multi-component systems, consisting of a stent, a carrier vehicle and a drug. The Endeavor stent demonstrates unique properties in each of these components. The stent is the recently introduced Medtronic Driver cobalt alloy stent with thin struts and an edgeless design. This stent is extremely flexible and deliverable. From a physician operator standpoint, the Endeavor stent can be delivered more easily to portions of the coronary tree that would be difficult to access with earlier generation DES. The drug carrier system is a biocompatible hydrophilic polymer called phosphorylcholine, which is modeled using biomimicry to look like continued on page 8 Bay Regional Medical Center Scott Fylling, RCIS, Cath Lab Manager, Willa Rousseau, BSN, Cath Lab Director, Bay City, Michigan. Interviewed by Karen DiDonato, RN, MSN, Abbott Vascular, Redwood City, California What is the size of your cath lab facility and number of staff members? We have 39 full-time employees (FTEs), consisting of: • 2 management staff; • 7 cath lab registered nurses (RNs); • 6.4 RNs for the cardiovascular care unit (CVCU, pre and post); • 1 licensed practical nurse (LPN); • 2 cardiovascular technologists; • 4 registered cardiovascular invasive specialists (RCISs); • 2 clerks; continued on page 21 STEMI Interventions: Future Perspectives An excerpt from the upcoming Textbook of STEMI Interventions by Sameer Mehta, MD, FACC, MBA In Development Page 32 A 3D CT Vessel “Roadmap” Over Live Fluoroscopy for Chronic Total Occlusions Cath Lab Digest talks with Jeffrey W. Moses, MD Dr. Moses is Director of the Center for Interventional Vascular Therapy, New York-Presbyterian Hospital/Columbia University Medical Center; Director, Cardiac Catheterization Lab, New York-Presbyterian/Columbia University Medical Center; Professor of Medicine at Columbia University College of Physicians and Surgeons, New York, New York. Read the whole story on page 14 http://www.cathlabdigest.com

Table of Contents Feed for the Digital Edition of Cath Lab Digest - February 2008

Cath Lab Digest - February 2008 Bay Regional Medical Center ENDEAVOR IV: A Zotarolimus-Eluting Stent Versus a Paclitaxel-Eluting Stent in a Randomized Clinical Trial A 3D CT Vessel “Roadmap” Over Live Fluoroscopy for Chronic Total Occlusions Contents Clinical Editor’s Corner An Evaluation of Cath Lab Turnaround Time Commentary: An Evaluation of Cath Lab Turnaround Time Excerpts from Chapter 19. STEMI Interventions – Future Perspectives The Potential Clinical Utility of Intravascular Ultrasound Guidance in Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents The Ten-Minute Interview with…Debbie Charlton, RN The Society of Invasive Cardiovascular Professionals (SICP) at Transcatheter Cardiovascular Therapeutics (TCT) 2007 The Cath Lab is a Business: Do You Have the Knowledge to Stay Afloat? Incidence and Predictors of Vascular Complications after Invasive Coronary Procedures: A Prospective Analysis Ask the Clinical Instructor: A Q&A Column for those New to the Cath Lab Volunteer Survey SICP* Section Meetings Calendar What Do You Think? CEU Education Center Clinical & Industry News Classifieds Advertisers Index

Cath Lab Digest - February 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.